Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./